S&P 500   4,297.29 (+0.22%)
DOW   33,466.77 (-0.12%)
QQQ   360.45 (+0.61%)
AAPL   173.42 (+1.29%)
MSFT   318.79 (+0.96%)
META   304.78 (+1.52%)
GOOGL   133.50 (+2.02%)
AMZN   129.16 (+1.60%)
TSLA   251.25 (+0.41%)
NVDA   448.69 (+3.15%)
NIO   8.81 (-2.54%)
BABA   86.19 (-0.63%)
AMD   102.33 (-0.48%)
T   14.85 (-1.13%)
F   12.26 (-1.29%)
MU   67.77 (-0.38%)
CGC   0.79 (+1.00%)
GE   109.37 (-1.07%)
DIS   81.02 (-0.04%)
AMC   7.93 (-0.75%)
PFE   33.37 (+0.60%)
PYPL   58.75 (+0.50%)
NFLX   380.71 (+0.82%)
S&P 500   4,297.29 (+0.22%)
DOW   33,466.77 (-0.12%)
QQQ   360.45 (+0.61%)
AAPL   173.42 (+1.29%)
MSFT   318.79 (+0.96%)
META   304.78 (+1.52%)
GOOGL   133.50 (+2.02%)
AMZN   129.16 (+1.60%)
TSLA   251.25 (+0.41%)
NVDA   448.69 (+3.15%)
NIO   8.81 (-2.54%)
BABA   86.19 (-0.63%)
AMD   102.33 (-0.48%)
T   14.85 (-1.13%)
F   12.26 (-1.29%)
MU   67.77 (-0.38%)
CGC   0.79 (+1.00%)
GE   109.37 (-1.07%)
DIS   81.02 (-0.04%)
AMC   7.93 (-0.75%)
PFE   33.37 (+0.60%)
PYPL   58.75 (+0.50%)
NFLX   380.71 (+0.82%)
S&P 500   4,297.29 (+0.22%)
DOW   33,466.77 (-0.12%)
QQQ   360.45 (+0.61%)
AAPL   173.42 (+1.29%)
MSFT   318.79 (+0.96%)
META   304.78 (+1.52%)
GOOGL   133.50 (+2.02%)
AMZN   129.16 (+1.60%)
TSLA   251.25 (+0.41%)
NVDA   448.69 (+3.15%)
NIO   8.81 (-2.54%)
BABA   86.19 (-0.63%)
AMD   102.33 (-0.48%)
T   14.85 (-1.13%)
F   12.26 (-1.29%)
MU   67.77 (-0.38%)
CGC   0.79 (+1.00%)
GE   109.37 (-1.07%)
DIS   81.02 (-0.04%)
AMC   7.93 (-0.75%)
PFE   33.37 (+0.60%)
PYPL   58.75 (+0.50%)
NFLX   380.71 (+0.82%)
S&P 500   4,297.29 (+0.22%)
DOW   33,466.77 (-0.12%)
QQQ   360.45 (+0.61%)
AAPL   173.42 (+1.29%)
MSFT   318.79 (+0.96%)
META   304.78 (+1.52%)
GOOGL   133.50 (+2.02%)
AMZN   129.16 (+1.60%)
TSLA   251.25 (+0.41%)
NVDA   448.69 (+3.15%)
NIO   8.81 (-2.54%)
BABA   86.19 (-0.63%)
AMD   102.33 (-0.48%)
T   14.85 (-1.13%)
F   12.26 (-1.29%)
MU   67.77 (-0.38%)
CGC   0.79 (+1.00%)
GE   109.37 (-1.07%)
DIS   81.02 (-0.04%)
AMC   7.93 (-0.75%)
PFE   33.37 (+0.60%)
PYPL   58.75 (+0.50%)
NFLX   380.71 (+0.82%)
NASDAQ:BMRN

BioMarin Pharmaceutical (BMRN) Stock Forecast, Price & News

$87.12
-1.36 (-1.54%)
(As of 11:09 AM ET)
Compare
Today's Range
$86.80
▼
$88.35
50-Day Range
$86.27
▼
$94.48
52-Week Range
$80.53
▼
$117.77
Volume
138,724 shs
Average Volume
1.30 million shs
Market Capitalization
$16.39 billion
P/E Ratio
167.54
Dividend Yield
N/A
Price Target
$115.62
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

BioMarin Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.55 Rating Score
Upside/​Downside
30.7% Upside
$115.62 Price Target
Short Interest
Bearish
3.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.93
Upright™ Environmental Score
News Sentiment
0.68mentions of BioMarin Pharmaceutical in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$2.87 M Sold Last Quarter
Proj. Earnings Growth
105.60%
From $1.25 to $2.57 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

83rd out of 969 stocks

Pharmaceutical Preparations Industry

24th out of 453 stocks

See Top Rated MarketRank™ Stocks Here

BMRN stock logo

About BioMarin Pharmaceutical (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN Price History

BMRN Stock News Headlines

September 25, 2023 | marketbeat.com
Are Gene Therapy Stocks The Market's Next Big Winners? (BMRN)
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
September 30, 2023 | msn.com
Raymond James Initiates Coverage of Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) with Market Perform Recommendation
October 2, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
September 30, 2023 | americanbankingnews.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Coverage Initiated at Raymond James
September 28, 2023 | markets.businessinsider.com
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
September 27, 2023 | americanbankingnews.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Rating of "Moderate Buy" from Brokerages
September 26, 2023 | americanbankingnews.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Given Buy Rating at Truist Financial
September 25, 2023 | stocknews.com
3 Biotech Stocks Offering Potential for Gains
October 2, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
September 21, 2023 | finance.yahoo.com
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
September 18, 2023 | finance.yahoo.com
BioMarin's share prices fluctuate following Phase 3 clinical trial results
September 15, 2023 | msn.com
Truist Securities Reiterates Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) Buy Recommendation
September 15, 2023 | markets.businessinsider.com
BioMarin Pharma: CHMP Adopts Positive Opinion To Expand Indication For VOXZOGO
September 15, 2023 | finance.yahoo.com
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
September 13, 2023 | markets.businessinsider.com
What 16 Analyst Ratings Have To Say About Biomarin Pharmaceutical
September 13, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT) and BioMarin Pharmaceutical (BMRN)
September 13, 2023 | markets.businessinsider.com
BioMarin Pharmaceutical (BMRN) Receives a Rating Update from a Top Analyst
September 11, 2023 | finance.yahoo.com
BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
September 6, 2023 | finance.yahoo.com
BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
September 5, 2023 | finance.yahoo.com
BioMarin to Participate in Three Upcoming Investor Conferences
September 1, 2023 | stocknews.com
3 Brilliant Biotech Stocks to Buy for Your Portfolio
August 31, 2023 | markets.businessinsider.com
Wedbush Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)
August 31, 2023 | finance.yahoo.com
Why Is Incyte (INCY) Down 0.7% Since Last Earnings Report?
August 30, 2023 | finance.yahoo.com
BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe
August 26, 2023 | finance.yahoo.com
Biomarin Pharmaceutical Inc (BM8.BE)
August 3, 2023 | markets.businessinsider.com
RBC Capital Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)
August 3, 2023 | markets.businessinsider.com
BioMarin Pharmaceutical (BMRN) Receives a Buy from Truist Financial
See More Headlines
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Company Calendar

Last Earnings
7/31/2023
Today
10/02/2023
Next Earnings (Estimated)
10/25/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BMRN
CUSIP
09061G10
CIK
1048477
Web
www.bmrn.com
Phone
(415) 506-6700
Fax
415-382-7889
Employees
3,082
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$115.62
High Stock Price Forecast
$185.00
Low Stock Price Forecast
$78.00
Forecasted Upside/Downside
+30.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.55
Research Coverage
22 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.52
Trailing P/E Ratio
170.16
Forward P/E Ratio
70.78
P/E Growth
N/A
Net Income
$141.56 million
Net Margins
4.47%
Pretax Margin
4.84%
Return on Equity
4.03%
Return on Assets
2.93%

Debt

Debt-to-Equity Ratio
0.23
Current Ratio
4.94
Quick Ratio
3.31

Sales & Book Value

Annual Sales
$2.10 billion
Price / Sales
7.94
Cash Flow
$1.47 per share
Price / Cash Flow
60.05
Book Value
$24.82 per share
Price / Book
3.56

Miscellaneous

Outstanding Shares
188,180,000
Free Float
184,713,000
Market Cap
$16.65 billion
Optionable
Optionable
Beta
0.36

Social Links

(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Jean-Jacques Bienaime M.B.A.Mr. Jean-Jacques Bienaime M.B.A. (Age 70)
    MBA, Chairman & CEO
    Comp: $3.52M
  • Mr. Brian R. MuellerMr. Brian R. Mueller (Age 49)
    CFO & Exec. VP
    Comp: $1.15M
  • Mr. George Eric DavisMr. George Eric Davis (Age 52)
    Exec. VP, Chief Legal Officer, Gen. Counsel & Sec.
    Comp: $1.23M
  • Mr. Jeffrey Robert AjerMr. Jeffrey Robert Ajer (Age 61)
    Chief Commercial Officer
    Comp: $1.18M
  • Dr. Henry J. Fuchs M.D. (Age 65)
    Ph.D., Pres of Worldwide R&D
    Comp: $1.49M
  • Ms. Erin Burkhart
    Group VP & Chief Accounting Officer
  • Dr. Kevin Eggan Ph.D.
    Chief Scientific Officer & Sr. VP of Research and Early Devel.
  • Traci McCarty
    Group VP of Investor Relations
  • Mr. Philip Lo Scalzo
    Chief Compliance Officer
  • Ms. Marni Kottle
    Chief Communications Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BMRN Stock - Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 1 sell rating, 8 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMRN shares.
View BMRN analyst ratings or view top-rated stocks.

What is BioMarin Pharmaceutical's stock price forecast for 2023?

22 analysts have issued 12-month price targets for BioMarin Pharmaceutical's shares. Their BMRN share price forecasts range from $78.00 to $185.00. On average, they expect the company's share price to reach $115.62 in the next year. This suggests a possible upside of 30.7% from the stock's current price.
View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts.

How have BMRN shares performed in 2023?

BioMarin Pharmaceutical's stock was trading at $103.49 at the start of the year. Since then, BMRN shares have decreased by 14.5% and is now trading at $88.48.
View the best growth stocks for 2023 here.

Are investors shorting BioMarin Pharmaceutical?

BioMarin Pharmaceutical saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 6,570,000 shares, an increase of 5.1% from the August 31st total of 6,250,000 shares. Based on an average trading volume of 1,290,000 shares, the days-to-cover ratio is currently 5.1 days.
View BioMarin Pharmaceutical's Short Interest.

When is BioMarin Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 25th 2023.
View our BMRN earnings forecast.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its quarterly earnings results on Monday, July, 31st. The biotechnology company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.24 by $0.10. The biotechnology company had revenue of $595.28 million for the quarter, compared to analysts' expectations of $591.46 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 4.03% and a net margin of 4.47%.

What ETFs hold BioMarin Pharmaceutical's stock?

ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), VanEck Biotech ETF (BBH), BNY Mellon Innovators ETF (BKIV), First Trust Innovation Leaders ETF (ILDR) and VictoryShares Nasdaq Next 50 ETF (QQQN).

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY 2023 earnings guidance on Monday, July, 31st. The company provided EPS guidance of $1.85-$2.10 for the period, compared to the consensus earnings per share estimate of $1.02. The company issued revenue guidance of $2.38 billion-$2.50 billion, compared to the consensus revenue estimate of $2.46 billion.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $88.48.

How much money does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $16.65 billion and generates $2.10 billion in revenue each year. The biotechnology company earns $141.56 million in net income (profit) each year or $0.52 on an earnings per share basis.

How many employees does BioMarin Pharmaceutical have?

The company employs 3,082 workers across the globe.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889.

This page (NASDAQ:BMRN) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -